Atlas Arteria Limited (OTCMKTS:MAQAF – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totaling 5,755,870 shares, a growth of 264.3% from the June 15th total of 1,579,770 shares. Based on an average trading volume of 2,955 shares, the short-interest ratio is currently 1,947.8 days.
Atlas Arteria Stock Performance
Shares of OTCMKTS:MAQAF remained flat at $4.09 during trading on Tuesday. 800 shares of the stock traded hands, compared to its average volume of 1,333. Atlas Arteria has a twelve month low of $2.69 and a twelve month high of $4.09. The company has a 50-day moving average of $3.46 and a 200 day moving average of $3.34.
Analyst Upgrades and Downgrades
Separately, Royal Bank Of Canada lowered shares of Atlas Arteria to an “underperform” rating and set a $4.75 price objective on the stock. in a report on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Atlas Arteria currently has a consensus rating of “Sell” and an average price target of $4.75.
About Atlas Arteria
Atlas Arteria (OTCMKTS: MAQAF) is a global toll road owner and operator specializing in the development, management and long-term investment of transport infrastructure. The company partners with governments and institutional investors to acquire, manage and optimise concession-based road assets, generating stable revenue streams through user fees and toll collections. Atlas Arteria focuses on enhancing traffic flow and safety through targeted capital improvements and operational efficiencies across its portfolio.
The company’s primary assets span North America, Europe and Australia.
Further Reading
- Five stocks we like better than Atlas Arteria
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Atlas Arteria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlas Arteria and related companies with MarketBeat.com's FREE daily email newsletter.
